GMR Solutions Inc. GMRS PHARMA
Company Overview
GMR Solutions Inc. operates as a provider of emergency medical services (EMS), essential alternate-site, out-of-hospital care, and mobile clinical practice groups in United States. It offers emergent medical services; non-emergent services; and other solutions, such as membership programs, standby and special events, national ambulance contract with the federal emergency management agency, and other state agency and health system contracts to coordinate EMS responses. It serves health systems, large regional systems, and smaller independent hospitals, local communities, health systems, payors, public health and local, state, and federal agencies. The company was incorporated in 2015 and is headquartered in Lewisville, Texas.
Why Investors Should Care
Generates a return on equity of 101.0%, reflecting efficient use of shareholder capital.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $5.74B (-4.0% YoY); net profit $206.23M.
- Trailing 12 Months Year-on-year growth — revenue +3.3%, earnings +910.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.15% |
| 1 Year: | 3.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 910.47% |
Stock Price Performance
| 1 Year: | -1.29% |
| 6 Months: | - |
| 3 Months: | +30.43% |
| 1 Month: | +9.70% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)56.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 101.0%.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GMRS GMR Solutions Inc. PHARMA | 13.80 | -6.80 | $745.50M | 0.00% | 12.84% | 101.01% | 3.15% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 1.37B | 1.46B |
| Cost of Revenue | 846.57M | 888.63M |
| Gross Profit | 520.84M | 568.95M |
| Operating Expenses | 324.58M | 346.44M |
| Operating Income | 196.25M | 222.51M |
| EBITDA | 256.20M | 301.07M |
| Interest Expense | 113.69M | 83.17M |
| Pretax Income | 67.39M | 142.53M |
| Tax Provision | 29.37M | 36.20M |
| Net Income | 38.02M | 106.34M |
| Diluted EPS | 0.17 | 1.97 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 5.39B | 5.98B | 5.74B |
| Cost of Revenue | 3.32B | 3.54B | 3.51B |
| Gross Profit | 2.08B | 2.44B | 2.23B |
| Operating Expenses | 1.66B | 1.72B | 1.41B |
| Operating Income | 421.11M | 721.52M | 824.12M |
| EBITDA | 675.02M | 911.57M | 1.07B |
| Interest Expense | 521.16M | 499.25M | 422.67M |
| Pretax Income | -160.59M | 114.52M | 316.53M |
| Tax Provision | 42.07M | 94.11M | 110.30M |
| Net Income | -202.66M | 20.41M | 206.23M |
| Diluted EPS | -0.91 | -0.32 | 0.16 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 7.12B | 7.48B |
| Current Assets | 1.82B | 2.13B |
| Cash & Equivalents | 352.29M | 609.35M |
| Inventory | 105.70M | 115.72M |
| Receivables | 1.08B | 1.09B |
| Total Liabilities | 6.93B | 7.28B |
| Current Liabilities | 1.02B | 1.06B |
| Long Term Debt | 4.38B | 4.90B |
| Total Debt | 4.86B | 5.37B |
| Total Equity | 188.00M | 204.16M |
| Shares Outstanding | 54.02M | 54.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 257.75M | 246.21M | 641.15M |
| Investing Cash Flow | -142.97M | 47.97M | -249.97M |
| Financing Cash Flow | -142.18M | -59.24M | -135.84M |
| Capital Expenditure | -171.01M | -268.62M | -258.54M |
| Free Cash Flow | 86.74M | -22.41M | 382.60M |
| Net Change in Cash | -27.39M | 234.94M | 255.33M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 38.5% | 40.8% | 38.9% |
| Operating Margin % | 7.8% | 12.1% | 14.4% |
| Net Margin % | -3.8% | 0.3% | 3.6% |
| ROE % | - | 10.9% | 101.0% |
| ROCE % | - | 11.8% | 12.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kohlberg Kravis Roberts & Co. L.P. | 27.37% | 14.79M | $185.26M |
| 2 | FMR, LLC | 6.22% | 3.36M | $42.11M |
| 3 | Citadel Advisors Llc | 5.90% | 3.19M | $39.94M |
| 4 | Invesco Ltd. | 5.72% | 3.09M | $38.70M |
| 5 | NORGES BANK | 5.46% | 2.95M | $36.96M |
| 6 | Healthcare of Ontario Pension Plan Trust Fund | 4.44% | 2.40M | $30.07M |
| 7 | Alyeska Investment Group, L.p. | 4.41% | 2.38M | $29.84M |
| 8 | Koch, Inc. | 4.08% | 2.20M | $27.62M |
| 9 | Alberta Investment Management Corp | 2.81% | 1.52M | $19.01M |
| 10 | Ensign Peak Advisors, Inc | 2.35% | 1.27M | $15.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GMRS
GMR Solutions Inc. (GMRS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPb1VsdHhlRkx6dUY1bzZCQlRzWFU2UHJSaVk0dl9WYUNLSXp1czN4eEo5X0g0MFlXSVFLWEJOVlhMRWtNVDRzTklnMllaTktOSGwxYXNLZmdsdEVaYlhybC1DU1lqWTk5SW9NZkozcFJMWVRYTWJwM21CWGF0eGdUa0tkQzdOLVhaQzRiTW…
GMR Solutions (GMRS) insider logs stock transaction - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQbEJUcXFEUlhodTZQMlVKS0xnRWJ4ZUJmdF9OZ2didkJtdElpdzJIYUJKRUlEdjhZV2dGMzR1Z3hGc0N4R3dhQkx5YVpNSWowS2tBYlIxbktaeGRlNjVGMTNFeVdfNXhwNVhxbVNwZlRQVUNoZUNqLVF2QWNXbVBMaDYybW5wcjl5ZGVRMm…
GMRS Stock Price and Chart — NYSE:GMRS - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE9kWTZ0RjdLUmxudkdZaEwyeWpBMnpRRExjWVpHX3FmaXVEdE8wUE43LWdqN3hDZWRqVGllejV0WFRndnFTUVhQQU1NOEpYeDUzeFEwX0ktVGdhZw?oc=5" target="_blank">GMRS Stock Price and Chart — NYSE:GMRS</a>&nb…
GMR Solutions Stock: The Post-IPO Discount Looks Too Harsh (NYSE:GMRS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNUDQ0Y0xNNS15bUxycWticG15aHZILWx3WGxmM3BXbk5Nc05HWGFxWTNNQWJ2Q0Z0WWppTEhoclNnYUoxQlVoaWdBUWtDRDVsam9ScEhJNll4Q0xGclR1ZFVZenpsQUFqaGd2cUlrSXpMaVVvR2hyd2c5WDFxX2RTbUxGUkZZaGRNeDljQU…
GMRS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE82S0h2TlQ3dmJqTktmbklWTWdlMlZOMm0yNFZTTXVCRVdQLWIwXzJ3UUdBakhYN2dSMDRLMjRVbVJoSkRlZHc?oc=5" target="_blank">GMRS</a> <font color="#6f6f6f">Finviz</font>…
What is the current Price Target and Forecast for GMR Solutions Inc. (GMRS) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE81djhHRUxMaDA3eDNCYlg1X2NNU0Jmd3NJa3k3MGpMaXY0SzJCbFlhNDJqNVd6VlhqSG1SMEsyVG40S0QtTTQ4VFMtNVAwdFl1ZWI3TUhVTmw0SXd5bGdoelVFMl9jV3NRQnNyVThvX2U4TUpkcUpHeA?oc=5" target="_blank">What …
GMRS — Frequently Asked Questions
What is the current share price of GMR Solutions Inc. (GMRS)?
As of 2026-09-19 21:16 PDT, GMR Solutions Inc. (GMRS) trades at $13.80 on NYSE. Its 52-week range is $10.58 to $15.74.
What is the market capitalisation of GMRS?
GMR Solutions Inc. (GMRS) has a market capitalisation of $745.50M on NYSE.
What is the P/E ratio of GMRS?
GMRS trades at a trailing price-to-earnings (P/E) ratio of -6.80. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.23.
What is the return on equity (ROE) of GMRS?
GMRS has a return on equity (ROE) of 101.01%. Its return on capital employed (ROCE) is 12.84%.
Is GMRS a good stock to buy?
This page provides a data-driven analysis of GMR Solutions Inc. (GMRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.